Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNOCAPA: Inhaled Nitric Oxide for Cardiac Arrest
NCT05868109Phase 2Recruiting
- Sponsor
- SickKids
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitric oxide in cardiac arrest (SCA) (2 arms), sponsored by SickKids. Primary endpoints: Drug Procedural Feasibility (Enrollment Rates) at 2 years and Drug Procedural Feasibility (Intervention Compliance) at 72 hours. Started Aug 2022; status: recruiting.
02
Drugs
nitric oxide
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT05868109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868109.